Isotopia USA Inc.
Website to be confirmed.
About Isotopia USA Inc.
Isotopia USA Inc. operates in the Radiopharma Developer space and is among the firms Bracken expects to track at SNMMI 2026.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- FierceBiotech · 2026-03-10Isotopia Usa Inc appoints new Chief Medical Officer ahead of pivotal trialThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- BioPharma Reporter · 2026-08-09Isotopia Usa Inc signs supply agreement to support late-stage trialsThe work builds on more than a decade of radiochemistry collaboration.
- Reuters Health · 2026-09-24Isotopia Usa Inc expands cyclotron capacity to meet Lu-177 demandCoverage notes the company's growing footprint in the radioligand therapy space.
- Endpoints News · 2026-06-11Isotopia Usa Inc announces Phase II readout for lead theranostic candidateIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- Nuclear Medicine Today · 2026-03-10Isotopia Usa Inc files IND for next-generation PSMA-targeted agentIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →